Skip to Content
Home > Services > Cancer > Clinical Research Trials > Clinical Trial Search > Detail
Back to Results
This Phase 2, open-label study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of Tomivosertib (eFT-508) in subjects who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no evidence of partial response (PR) or complete response (CR).
Kenneth A. Kuenzli II, RN864email@example.com
Thank you for your feedback!
Get the latest news on the health topics that matter most to you.
© 2019 Spartanburg Regional Healthcare System. All Rights Reserved.